137 results
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Jul 24
Interim Consolidated Financial Statements
8:35am
, the “Marathon Adjusted EBITDA”) targets over the most recently ended four fiscal quarters; and, (ii) minimum Marathon Adjusted EBITDA targets over the most
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Jul 24
Interim Consolidated Financial Statements
8:35am
$15,000 and $20,000, based on the Marathon Adjusted EBITDA (as defined in the Marathon Credit Agreement, the “Marathon Adjusted EBITDA”) targets over … the most recently ended four fiscal quarters; and (ii) minimum Marathon Adjusted EBITDA targets over the most recently ended four fiscal quarters. A breach
6-K
EX-99.1
THTX
Theratechnologies Inc.
10 Jul 24
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
8:35am
in the Marathon Credit Agreement, the “Marathon Adjusted EBITDA”) targets over the most recently ended four fiscal quarters; and, (ii) minimum Marathon … Adjusted EBITDA targets over the most recently ended four fiscal quarters. The breach of a covenant provides the lender with the ability to demand immediate
6-K
EX-99.2
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
of financial targets and corporate milestones each accounted for 30% of the total bonus.
Financial targets were based as to 15% on the attainment of pre … EBITDA”) targets. The Adjusted EBITDA targets are not disclosed since the Corporation did not provide any specific Adjusted EBITDA targets as part
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
, the “Marathon Adjusted EBITDA”) targets over the most recently ended four fiscal quarters; and, (ii) quarterly minimum Marathon Adjusted EBITDA targets
6-K
EX-99.1
icr k6ry37
10 Apr 24
Interim Consolidated Financial Statements
8:30am
6-K
EX-99.1
3ba6i7cv 8w03
10 Apr 24
Theratechnologies Reports Financial Results
8:16am
6-K
EX-99.1
cjwf7u39m4zej 1ukyn
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
EX-99.1
7ltwsvh t1y0mf2p71n0
15 Feb 24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
8:36am
SUPPL
9rs0wjn 28
26 Oct 23
Supplemental materials (foreign)
9:13pm
SUPPL
jm84ba
25 Oct 23
Supplemental materials (foreign)
6:56pm
6-K
EX-99.1
ib6 3f6wcu7b1a
16 Oct 23
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
3:04pm
6-K
EX-99.1
hokzpoe ljzu
26 Sep 23
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
8:02am
6-K
EX-99.1
qzc8vbgnm
26 Sep 23
Interim Consolidated Financial Statements
8:00am